From January 9 to 10, 2025, the 8th In-depth Focus Summit on Cell and Gene Therapy (ICGT 2025) was grandly opened in Shanghai. As the largest annual event in the domestic cell and gene therapy industry, this summit attracted Global attention. Relying on its outstanding performance and active exploration in the industry, Shanghai Kepeixing Biomedical Research Co., Ltd. was invited to attend this summit, gathering together with more than 80 leading experts and more than 1,000 industry elites from all over the world. Conduct in-depth exchanges and discussions on cutting-edge technologies, key links in the industrial chain, innovative concepts and future development trends in the field of cell and gene therapy.
Cell and gene therapy (CGT), as a frontier direction with the greatest potential in the field of biomedicine in recent years, has made remarkable achievements in clinical application. Especially in medical problems such as autoimmune diseases, rare diseases, and tumor treatment, it has opened up new treatment paths for countless patients and brought hope of cure. This ICGT 2025 summit precisely focuses on key technological breakthroughs in the treatment of autoimmune diseases and solid tumors. It also provides an in-depth analysis of industry development bottlenecks such as how to effectively reduce R&D costs and accelerate clinical transformation, striving to promote the steady progress of the CGT industry in an all-round way.
Representatives from Shanghai Kepeixing Biomedical Research Co., Ltd. expressed emotion during the summit that this summit is a rare industry exchange feast. During the two-day agenda, the company team actively participated in all aspects, deeply studied the latest research results of cellular immunotherapy in the treatment of solid tumors, fully grasped the cutting-edge progress in the field of rare disease treatment, and also discussed with many peers the role of CRO in the treatment of solid tumors. The key roles played in the CGT industry chain were discussed in depth. Through the collision of ideas with industry pioneers, the company gained valuable industry insights and also shared how to help CGT R&D companies optimize the R&D process and shorten R&D through efficient project management, strict quality control and cutting-edge technical support. cycle and reduce R&D costs, providing a new perspective and direction for subsequent R&D cooperation strategic planning.
In addition, Shanghai Kepeixing Biomedical Research Co., Ltd. actively participated and launched fruitful negotiations with many potential partners, aiming to explore high-quality CGT projects, further consolidate the company's strategic layout in the field of cell and gene therapy, integrate resources, and join hands Make progress together to promote technological innovation and application expansion in the industry. The company hopes to establish long-term and stable cooperative relationships with more partners and use its CRO service advantages to provide them with one-stop solutions from preclinical research to clinical trials.
By participating in this conference, Shanghai Kepeixing Biomedical Research Co., Ltd. not only deeply integrated into the development trend of the industry and accurately grasped the pulse of industry trends, but also demonstrated to the outside world the company's firm determination to work hard and forge ahead as a CRO in the field of cell and gene therapy. with a positive attitude. Looking forward to the future, Shanghai Kepeixing Biomedical Research Co., Ltd. will continue to adhere to the innovation-driven development concept, deeply explore the potential of cell and gene therapy technology, and strive to bring more efficient and safe treatment options to Chinese patients, and promote the development of Chinese medicine. Contribute to the development of health industry.
